Lucid Diagnostics Inc (LUCD): רווח נקי למניה (EPS TTM)
Physician confidence in esophageal cancer diagnostic methods strengthens the position of Lucid Diagnostics Inc. (LUCD). This 12-month net income per share chart demonstrates the current resilience of the business, where the metric stands at -0.47. The innovative EsoGuard test replaces endoscopy, simplifying screening. The company's strong pricing power is supported by the critical importance of early pathology detection via unique DNA analysis.
פילוחי נתונים אנליטיים מרוכזים עבור Lucid Diagnostics, Inc. (LUCD)
The commercialization efficiency of EsoGuard tests for diagnosing precancerous esophageal conditions is directly reflected in the earnings per share dynamics of Lucid Diagnostics Inc. (LUCD). This calculation combines annual net income with the total number of issued shares, allowing for an assessment of the business's real profitability amid tight monetary policy. Analyzing the TTM annual earnings per share helps investors recognize the risk of overpaying for the asset in a timely manner.
